申请人:Merrell Pharmaceuticals Inc.
公开号:US05648365A1
公开(公告)日:1997-07-15
Diarylalkyl piperidines of formula (1) ##STR1## reverse drug resistance in multi-drug resistant tumors. These compounds apparently function by inhibiting a p-glycoprotein pump which becomes activated in late stage tumor development and which is inherently present in tumors from certain origins.
化学式(1)中的二芳基烷基哌啶似乎通过抑制p-糖蛋白泵来逆转多药耐药性肿瘤。这些化合物显然通过抑制在肿瘤晚期发展中被激活的p-糖蛋白泵来发挥作用,并且在某些起源的肿瘤中固有存在。